
Please note that any information that you supply is protected by our Privacy and Cookies Policy.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
Vetter Pharma International GmbH
Established: 1953
Number of staff: 2,700
Key Personnel: Max Horn, managing director; Thomas Otto, managing director; Peter Soelkner, managing director
Who we are:
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with a broad array of compounds, including monoclonal antibodies, peptides, interferons and vaccines. Combining state-of-the-art technology with innovative processes, Vetter can preserve API and helps reduce time-to-market. The firm supports clients from preclinical development through global market supply. Vetter works with the world´s leading pharmaceutical and biotech companies and offers a more than 25-year history of quality, innovation and strategic partnership. The new Chicago facility, an expansion of Vetter Development Service, provides early-stage product support.
Major Markets: Europe, North America and Japan
Services Offered:
Vetter Development Service includes:
Vetter Commercial Manufacturing includes:
Vetter Solutions include:
Dosage forms: Syringes, cartridges, vials